Quest PharmaTech (CVE:QPT) Trading Down 25% – Here’s Why

Quest PharmaTech Inc. (CVE:QPT) shares traded down 25% during mid-day trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03. 123,238 shares changed hands during mid-day trading, an increase of 444% from the average session volume of 22,666 shares. The stock had previously closed at C$0.04.

Quest PharmaTech Stock Down 25.0%

The company has a market cap of C$5.07 million, a price-to-earnings ratio of -30.00 and a beta of 0.00. The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40. The business’s 50 day simple moving average is C$0.04 and its 200-day simple moving average is C$0.04.

Quest PharmaTech Company Profile

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.